Published in Eur Radiol on September 03, 2015
Label-free CEST MRI Detection of Citicoline-Liposome Drug Delivery in Ischemic Stroke. Theranostics (2016) 0.79
Black blood T1rho MR imaging may diagnose early stage liver fibrosis: a proof-of-principle study with rat biliary duct ligation model. Quant Imaging Med Surg (2016) 0.75
MRI-CEST assessment of tumour perfusion using X-ray iodinated agents: comparison with a conventional Gd-based agent. Eur Radiol (2016) 0.75
Liver biopsy. N Engl J Med (2001) 9.91
Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat Med (2003) 6.57
Amide proton transfer (APT) contrast for imaging of brain tumors. Magn Reson Med (2003) 4.57
Assessment of glycosaminoglycan concentration in vivo by chemical exchange-dependent saturation transfer (gagCEST). Proc Natl Acad Sci U S A (2008) 4.43
MRI detection of glycogen in vivo by using chemical exchange saturation transfer imaging (glycoCEST). Proc Natl Acad Sci U S A (2007) 3.97
Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med (1993) 3.83
Water saturation shift referencing (WASSR) for chemical exchange saturation transfer (CEST) experiments. Magn Reson Med (2009) 3.57
Magnetic resonance imaging of glutamate. Nat Med (2012) 3.17
In vivo imaging of glucose uptake and metabolism in tumors. Nat Med (2013) 3.01
Amide proton transfer imaging of human brain tumors at 3T. Magn Reson Med (2006) 2.87
Early detection of steatohepatitis in fatty rat liver by using MR elastography. Radiology (2009) 2.12
T1rho MR imaging is sensitive to evaluate liver fibrosis: an experimental study in a rat biliary duct ligation model. Radiology (2011) 2.05
Investigation of optimizing and translating pH-sensitive pulsed-chemical exchange saturation transfer (CEST) imaging to a 3T clinical scanner. Magn Reson Med (2008) 2.01
Liver fibrosis. Biochem J (2008) 1.97
Natural D-glucose as a biodegradable MRI contrast agent for detecting cancer. Magn Reson Med (2012) 1.84
MR imaging of the amide-proton transfer effect and the pH-insensitive nuclear overhauser effect at 9.4 T. Magn Reson Med (2012) 1.67
Nuclear Overhauser enhancement (NOE) imaging in the human brain at 7T. Neuroimage (2013) 1.58
Modeling liver fibrosis in rodents. Methods Mol Med (2005) 1.57
Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately? J Hepatol (2008) 1.53
Three-dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement. J Magn Reson Imaging (2013) 1.43
Quantitative separation of CEST effect from magnetization transfer and spillover effects by Lorentzian-line-fit analysis of z-spectra. J Magn Reson (2011) 1.40
Imaging the tissue distribution of glucose in livers using a PARACEST sensor. Magn Reson Med (2008) 1.35
Development and validation of a smoothing-splines-based correction method for improving the analysis of CEST-MR images. Contrast Media Mol Imaging (2008) 1.35
Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab (2012) 1.20
Suppression of lipid artifacts in amide proton transfer imaging. Magn Reson Med (2005) 1.19
APT-weighted and NOE-weighted image contrasts in glioma with different RF saturation powers based on magnetization transfer ratio asymmetry analyses. Magn Reson Med (2013) 1.18
Terahertz spectroscopy of liver cirrhosis: investigating the origin of contrast. Phys Med Biol (2010) 1.17
Optimizing pulsed-chemical exchange saturation transfer imaging sequences. Magn Reson Med (2011) 1.16
Inverse Z-spectrum analysis for spillover-, MT-, and T1 -corrected steady-state pulsed CEST-MRI--application to pH-weighted MRI of acute stroke. NMR Biomed (2014) 1.11
Simulation and optimization of pulsed radio frequency irradiation scheme for chemical exchange saturation transfer (CEST) MRI-demonstration of pH-weighted pulsed-amide proton CEST MRI in an animal model of acute cerebral ischemia. Magn Reson Med (2011) 1.08
Nitric oxide protection of rat liver from lipid peroxidation, collagen accumulation, and liver damage induced by carbon tetrachloride. Biochem Pharmacol (1998) 1.07
Liver T1ρ MRI measurement in healthy human subjects at 3 T: a preliminary study with a two-dimensional fast-field echo sequence. Br J Radiol (2012) 1.06
Quantitative assessment of amide proton transfer (APT) and nuclear overhauser enhancement (NOE) imaging with extrapolated semi-solid magnetization transfer reference (EMR) signals: Application to a rat glioma model at 4.7 tesla. Magn Reson Med (2015) 1.03
Noninvasive evaluation of hepatic fibrosis using serum fibrotic markers, transient elastography (FibroScan) and real-time tissue elastography. Intervirology (2008) 1.03
Assessment of glycosaminoglycan distribution in human lumbar intervertebral discs using chemical exchange saturation transfer at 3 T: feasibility and initial experience. NMR Biomed (2011) 1.02
MR quantitative biomarkers of non-alcoholic fatty liver disease: technical evolutions and future trends. Quant Imaging Med Surg (2013) 1.00
Evaluation of fibrotic liver disease with whole-liver T1ρ MR imaging: a feasibility study at 1.5 T. Radiology (2013) 1.00
Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol (2006) 1.00
Conformational characterization of ceramides by nuclear magnetic resonance spectroscopy. Biophys J (2002) 0.98
Quantitative Bayesian model-based analysis of amide proton transfer MRI. Magn Reson Med (2012) 0.97
Optimized efficient liver T(1ρ) mapping using limited spin lock times. Phys Med Biol (2012) 0.94
Experimental evaluation of accelerated T1rho relaxation quantification in human liver using limited spin-lock times. Korean J Radiol (2012) 0.94
Evaluation of hepatic fibrosis using intravoxel incoherent motion in diffusion-weighted liver MRI. J Comput Assist Tomogr (2014) 0.93
Review of experimental models for inducing hepatic cirrhosis by bile duct ligation and carbon tetrachloride injection. Acta Cir Bras (2012) 0.92
Measurement of liver T₁ and T₂ relaxation times in an experimental mouse model of liver fibrosis. J Magn Reson Imaging (2012) 0.90
Assessment of the liver strain among cirrhotic and normal livers using tagged MRI. J Magn Reson Imaging (2012) 0.89
Evaluation of liver fibrosis with T1ρ MR imaging. Quant Imaging Med Surg (2014) 0.88
Current status of fibrosis markers. Curr Opin Gastroenterol (2014) 0.87
Observation of true and pseudo NOE signals using CEST-MRI and CEST-MRS sequences with and without lipid suppression. Magn Reson Med (2014) 0.86
Increase of ceramide in the liver and plasma after carbon tetrachloride intoxication in the rat. J Nutr Sci Vitaminol (Tokyo) (2007) 0.85
Accelerated T1rho relaxation quantification in intervertebral disc using limited spin-lock times. Quant Imaging Med Surg (2013) 0.84
Further exploration of MRI techniques for liver T1rho quantification. Quant Imaging Med Surg (2013) 0.84
Amide proton transfer-weighted imaging of the head and neck at 3 T: a feasibility study on healthy human subjects and patients with head and neck cancer. NMR Biomed (2014) 0.83
PANDA- T1ρ: Integrating principal component analysis and dictionary learning for fast T1ρ mapping. Magn Reson Med (2014) 0.83
Decreases in molecular diffusion, perfusion fraction and perfusion-related diffusion in fibrotic livers: a prospective clinical intravoxel incoherent motion MR imaging study. PLoS One (2014) 0.81
Assessment of glycosaminoglycan content in intervertebral discs using chemical exchange saturation transfer at 3.0 Tesla: preliminary results in patients with low-back pain. Eur Radiol (2012) 0.79
Aspartate transaminase to platelet ratio index (APRI) to assess liver fibrosis in patients with chronic liver disease. Hepat Mon (2011) 0.76